Mewburn Ellis advised MiRXES on the full IP workstream for its complex HKEx IPO, delivering the due diligence, FTO analysis and licensing review that enabled the company to achieve its US$1bn-plus public listing.
MiRXES is a Singapore-headquartered biotechnology company specialising in microRNA (miRNA) technology for early disease detection and precision medicine. Founded in 2014 as a spin-off from A*STAR’s Bioprocessing Technology Institute, the company develops non-invasive, blood-based diagnostic tests for major cancers, including breast, gastric, lung and colorectal cancer, as well as other diseases such as COVID. Its mission is to make early detection accessible globally by leveraging advanced RNA science to save lives.
Mewburn Ellis advised MiRXES on the IP aspects of its May 2025 IPO on the Hong Kong Stock Exchange, a complex, multi-stage transaction that began with HKEx, moved to the Singapore Stock Exchange and later returned to HKEx. Our work spanned several years and included full IP due diligence and extensive freedom-to-operate reporting, as well as detailed analysis of the company’s patent estate and in-licensing arrangements from Accelerate, A*STAR’s technology transfer arm, for inclusion in the listing prospectus.
The IPO will help fund the commercialisation of MiRXES’ diagnostics pipeline, and the company’s decision to entrust us with this significant transaction reflects our extensive experience advising on the IP aspects of IPOs and our established presence in Singapore, Korea and Japan. This milestone also marks MiRXES as the first Southeast Asian biotech firm to achieve a valuation exceeding US$1 billion through a public listing.
.jpeg)